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Introduction, welcome and updates 
On 30 September and 1 October 2021, the EMCDDA brought together more than 60 European and 
international experts for the annual meeting on the key indicator Drug-related deaths. The online 
meeting provided a space for sharing and discussing new data, studies and experiences at regional, 
national and European level. This meeting report provides an overview of presentations and 
discussion and is focused on the following topics.  
1. The 2020-21 update on the activities of the EMCDDA and the DRD network 
2. Preliminary analysis of the 2021 reports on drug-related deaths 
3. The COVID-19 pandemic, its impact on drug-related deaths data and trends 
4. Responses to overdoses  
5. Mortality cohort studies to answer key policy questions 
6. Drug-related deaths coding and assessment of the quality of the data 
The DRD network meeting brings together invited experts and experts nominated by the Reitox 
national focal points from the EU Member States, Norway and Turkey, the Western Balkans (through 
the IPA7 project), and the European Neighbourhood Policy countries (EU4MD project). Participating 
experts come from ministries of health, public health institutes, drugs agencies, universities, research 
institutes and civil society. This year, invited experts from Austria, Canada and France joined the 
expert meeting, and several new national experts attended the meeting.  
In the welcome and opening address, the EMCDDA stressed the importance of the national focal 
points and of the network of national experts, to contribute, through its support to the work of the 
agency to a healthier and safer Europe. Sound epidemiological monitoring based on robust sources 
and methods is now coupled with new more rapid methods. This information system contributes to the 
production of action-oriented information that can help the agency to answer key policy questions on 
fatal drug overdoses, other causes of deaths among drug users and responses to drug problems. In 
the current pandemic context, the network is, even more than usual, instrumental in documenting 
changes in the drug situation, conducting risk assessments and supporting evidence-based and 
informed policy-making.  
Trends 2020: preliminary findings and insights from selected countries 
Preliminary results and trends are discussed: it appears that most countries with data already 
available report stable numbers of drug-induced deaths in 2020 compared with 2019. This contrasts 
with the dramatic increases in the number of drug-induced deaths in 2020, compared with 2019, 
reported in both Canada and the United States (see Responses to overdoses: updates from the field).  
Consolidated analysis at a European level will only be available in 2022. In the meantime, national 
experts from selected countries presented their data and analysis.  
• Guus Cruts (the Netherlands): an ongoing increase is reported, driven mainly by opioids, 
among which heroin and methadone account for only a minority of the cases for which 
registration data are available to date. More data on the type of opioids involved are expected 
in the coming months, when the special register will provide more information. Many harm 
reduction facilities closed in the early phase of epidemic but opened again.  
• Patrizia Coda (Italy): provisional data suggest an overall lower number of deaths in 2020 
compared with 2019. In particular, the number of heroin-related deaths declined from 168 in 
2019 to 126 in 2020.  
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• Pirkko Kriikku (Finland): the number of drug-induced cases has increased over the past 
several years, with a notable year-on-year increase in 2020. As in previous years, opioids, 
buprenorphine in particular, dominate. The high proportion and the increase in the number of 
deaths among young males (under-25-year-olds) is a reason of concern (Rönkä et al., 2020) (1). 
In term of responses, in 2020, the Finnish Institute of Health and Welfare (THL) established an 
expert group (experts, staff from university, people who work with drug users etc.) to discuss 
and develop practical tools to counter the increase in drug-induced deaths.  
Caveats and limitations: Only about two thirds of the countries can report data for the year 2020. 
Large countries such as France, Germany, and Spain have still to report 2020 data, while they usually 
account for a large proportion of all reported drug-induced deaths in Europe. Most of the remaining 
countries have reported data for 2019. In Belgium, France and Ireland, only data older than 2019 will 
be available from the main data source. At the time of writing, not all data are received, and data are 
under validation with the national focal points and their drug-related deaths experts.  
Perceived impact of COVID-19 on drug-related deaths data and trends 
An interactive poll and discussion with the national experts followed, the results of which need to be 
cross-checked with the reported data over the coming weeks. A brief summary of the answers to the 
main questions is given below.  
• Did COVID-19 impact on the quality and or the completeness of the drug-related deaths data? 
Most experts reported that there was no such impact.  
• Did COVID-19 impact on the number of overdose deaths in 2020-2021? Most experts 
answered no.  
• Are there more overdoses with methadone or other opioid agonist medications implicated in 
2020-2021 compared with pre-COVID-19? Most experts answered no. Finland noted though 
that part of the increase in the overall number was related to substances mainly used for opioid 
agonist treatment (OAT), primarily buprenorphine (assumed to consist mostly of Subutex 
tablets that are smuggled to Finland from abroad rather than diverted from treatment) but also 
methadone (2). Ukraine reported an increase in the number of drug-induced deaths in 2020, in 
particular those deaths with methadone implicated. Adults aged 20-49 were those most 
affected by this increase.  
• Are there more overdoses with cocaine (powder/crack) implicated? Most countries answered 
no or that they do not know yet. Spain, where cocaine is commonly identified in half of the 
deaths, reported that no data were yet available for 2020. 
• Are there more overdoses with synthetic cannabinoids? Most countries reported no or that they 
did not know yet. Turkey reported that the number of deaths overall, and the deaths with these 
drugs, has continued to decrease after the peak observed in 2017. In 2020, heroin was 
implicated in about 4 out of 10 drug-induced deaths, while amphetamine and 
methamphetamine were implicated in 3 out of 10 deaths.  
 
(1) For reference, there were 31 100-44 300 problem users of amphetamines and opioids in Finland in 2017, 
which is 0.91-1.29 % of Finns aged 15-64. The number of high-risk drug users has nearly doubled from a 
previous study in 2012 and there was a particular increase in the age group 15-24 years.  
(2) Of note, the study Concomitant drugs with buprenorphine user deaths in Finland (Mariottini et al., 2021) 
showed that most poisoning deaths with buprenorphine implicated without other opioids (n = 271 over the 2016-
19 period) involved other drugs: benzodiazepines (94 %), illicit drugs (63 %), gabapentinoids (50 %), alcohol 
(41 %), antidepressants (32 %) and antipsychotics (28 %). Between 2016 and 2019, the annual number of these 
poisonings almost doubled (from 47 to 89 deaths) among those aged 15-64 years and more than tripled (from 9 
to 33 deaths) among those aged 15-24. Concomitant use of benzodiazepines, illicit and new psychoactive 
substances was significantly more common in the age-group 15-24 years than in the age-group 25-64 years. The 
results suggest particularly unsafe drug-use patterns in the younger age group, which requires rapid intervention. 
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• Other reasons for concern reported with regard to overdoses:  
• alcohol (i.e., an increase in alcohol-related mortality, reports from the services of an 
increase in the use of alcohol; association of alcohol and benzodiazepines); 
• most cases were mixed intoxications with illicit drugs and benzodiazepines; 
• an increase in the prescription of opioids (oxycodone and tramadol in particular); 
heroin and codeine were mentioned as well by several countries 
• deeper poverty; 
• an increase in mental health issues; 
• an increase in the number of young high-risk drug users; 
• some clients of the harm reduction facilities have been lost to follow-up and more 
outreach work is needed; 
• drug services reported some drug shortages but this varied by area, and most 
services reported that there was no disruptive effect of the pandemic on the local 
drug markets.  
Research papers from the drug-related deaths experts  
Trends in drug poisoning deaths, by sex, Ireland: a repeated cross-sectional study 2004-17  
Presentation by Ena Lynn, Ireland (Lynn et al., 2021) 
Objective: To examine sex differences in age-standardised rates (ASR) of overall and drug-specific 
drug poisoning deaths in Ireland between 2004 and 2017. Design: Repeated cross-sectional study. 
Participants: National Drug-Related Deaths Index (NDRDI) and pharmacy claims database (Primary 
Care Reimbursement Service-General Medical Services) data from 2004 to 2017. Outcome 
measures: Trends in drug poisoning death rates by sex; trends in death rates involving any CNS 
depressants; ≥2 CNS depressants; and specific drugs/drug classes (e.g., prescription opioids, 
benzodiazepines, antidepressants, alcohol, cocaine and heroin) by sex. Results: Increased ASR for 
all deaths from 2004 to 2017 was mainly driven by increasing deaths among men, with no significant 
change observed among women. Deaths involving ≥2 CNS depressants increased for both sexes. 
Drugs with the highest significant average annual percent change (AAPC) increases for men were 
cocaine, benzodiazepines, antidepressants and prescription opioids; and for women were 
antidepressants, benzodiazepines and prescription opioids. Conclusion: Drugs implicated vary by sex. 
Policy response should include prescription monitoring programmes and practical harm reduction 
information on polydrug use, especially CNS depressant drugs. The presence of pregabalin in drug 
poisoning deaths increased in Ireland from 15 cases (4.5 % of all drug poisoning deaths in 2013 to 94 
(26 %) in 2016 (Lynn et al., 2020). Opioid misuse and having a history of treatment for substance 
misuse was associated with an increased risk of presence of pregabalin. Other CNS depressant 
drugs were found almost systematically. Women were 3 times more likely to have two or more other 
CNS depressant drugs in toxicology than men.  
Pregabalin and gabapentin in non-opioid poisoning deaths in Finland  
Presentation by Pirkko Kriikku, Finland (Kriikku and Ojanpera, 2021) 
Background: a) Gabapentinoids are often connected to abuse of opioids (potentiate the effects of 
opioids; desired effects euphoria and relaxation; self-medication of opioid withdrawal symptoms); b) 
Medicinal use: 6 % increase for pregabalin and 4 % for gabapentin in Finland. Research questions: a) 
Is there abuse/misuse/overuse of gabapentinoids that is not connected to opioids? b) Have 
gabapentinoids been implicated in fatal poisonings without the contribution of opioids? Results: 
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Pregabalin implicated in non-opioid fatalities in 2016-2018: 51 cases (8.6 %) (out of 594 findings – of 
which 309 poisoning, of which 210 with pregabalin implicated). For gabapentin: 14 cases (4.5 % out 
of 313 findings – of which 121 poisoning, of which 70 with gabapentin implicated). Most cases also 
involve opioids. A minority of pregabalin poisonings (24 %) and gabapentin poisonings (20 %) 
involved no opioids. In most of these cases, other psychoactive substances were implicated in 
addition to the gabapentinoids. Still, some individuals (quite heterogeneous profiles) may be at risk of 
overdose by gabapentinoids even if no opioids are involved. 
Framework of the EMCDDA drug-related deaths and responses activities  
A summary of the five key activities of drug-related deaths monitoring in Europe was presented for 
reference, in particular for the new experts from EU and other countries.  
1. Quantify: Document how many drug-induced deaths occur, where and when. The current 
Statistical Bulletin is available since June 2021. The template for standard reporting of drug-
related deaths from the countries to the EMCDDA through FONTE has been revised, after 
consultation with the focal points and the national experts. This will facilitate, in particular, the 
collection of data on substances mentioned in the post-mortem investigation. 
2. Characterise: Document the substances detected in drug-induced deaths cases, but also the 
age and sex of the fatalities. More data and breakdowns are presented (e.g. in maps) in the 
FAQ DRD pages published in August 2021.  
3. Validate: Assess the quality of the drug-induced deaths data, by triangulation with other 
indicators such as estimations of prevalence of high-risk opioid use (HROU), number of 
people in opioid agonist treatment (OAT) and results from mortality cohort studies. 
4. Link with responses and inform policy-making. Updates on take-home naloxone and the 
prevention of overdose are available on the website; the 2017 European guide to health and 
social responses to drug use are being updated by a series of miniguides launched on a 
rolling basis from October 2021. 
5. Assess health threats: The drug-related deaths experts, together with emergency clinicians, 
drug treatment clinicians, public health specialists and representatives of the focal points have 
contributed to three ‘trendspotter’ studies: on the impact of the COVID-19 pandemic on 
services, published in May 2020; on drug use and harms, published in September 2020; and 
on drug markets, use and harm, published in May 2021.  
Responses to overdoses: updates from the field 
It was noted that based on the provisional data, there has not been a major change in the numbers of 
drug-induced deaths across Europe since the beginning of the COVID-19 pandemic. However, the 
intra-European differences in drug-induced deaths during the pandemic and the broad differences 
between North America and Europe are likely areas that merit further research and analysis.  
Situation and responses to the fentanyl crisis in British Columbia, Canada 
Presentation by Jean N. Westenberg, Canada 
In 2021, the number of overdose deaths in British Columbia are expected to surpass 2 000. This is 
being primarily driven by highly potent synthetic opioids such as fentanyl, reported in 85 % of the 
deaths. Safe consumption sites, recording 60 000+ visits per month, have been effective at reducing 
harms relating to substance use, but much more is needed. Guidelines allowing the provision of 
psychotropic substances (‘safe supply’) were implemented as a response to the COVID-19 pandemic, 
but the necessary data to concretely determine its effectiveness are not yet available. A large-scale 
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effective system response is needed, with fentanyl-assisted treatment being discussed as a potential 
approach (Krausz et al., 2021). 
Discussions: It was suggested that places with fairly strong institutions and access to services that are 
stable might have experienced fewer problems than places where these are less well-equipped. North 
America experienced multiple crises during 2020, and with the opioid crisis getting buried under the 
pandemic, more problems emerged and mortality skyrocketed. Those who are the most vulnerable, 
such as those with addictions, are most likely to suffer, and this is compounded by an absence of 
services and treatments for the most vulnerable. 
Crack cocaine: users’ trajectories, spatial mobility, needs and expectations, Paris region, 
France 
Presentation by Marie Jauffret-Roustide, France 
There were an estimated 44 000 people who use crack in 2019 in France (Janssen et al., 2020) 
including an estimated 13 000 in Paris region, other in French overseas territories, and signals of 
diffusion in cities like Bordeaux and Lille. Between half and a third of cocaine crack users are living in 
very precarious conditions; visibility in public spaces; major needs are safe consumption rooms, 
stable housing and psychiatric care; residents protests (NIMBY phenomenon).  
In September 2021, the French government (Ministry of Health) announced that new safe 
consumption rooms (four) will be implemented in Paris for people who use crack. The French 
Prefecture (Ministry of Interior at the Parisian level) decided to evacuate one of the major drug scenes 
that was located inside Paris to the suburbs (in a poorer area). The police built a wall to impede 
people who use crack to move (3). 
Mortality cohort studies 
EMCDDA project: European overview and mortality profiles 
Presentation by Martin Busch, Austria 
The EMCDDA initiated a project on mortality cohort studies in Europe, aiming to answer key policy 
questions about the overall mortality of people who use drugs in Europe, including the excess risk 
compared with the general population, the causes of deaths, and the impact of some interventions 
such as OAT. There is expertise and experience in many countries, but studies are sometimes not 
comparable, and their visibility could be improved. In this context, the project aims to produce a 
European overview and country profiles – for selected countries – of the most recent findings from 
cohort studies among people who use drugs. Although there are limitations in these studies (sub-
national coverage, findings not generalisable to all drug users, variety of settings, different populations 
and inclusion criteria), the project should facilitate the comparisons across studies and countries and 
the interpretation and use of the data.  
The methods used by the researchers (Tanja Schwarz and Martin Busch from the Austrian focal 
point) included a literature review, questionnaires and contacts with the drug-related deaths experts 
and focal points. The first results of the work are a) a draft ‘European overview’ or mapping of the 
existing studies, which was presented for discussion and feedback, and b) three draft ‘Mortality 
 
(3) The speaker suggested more references to ongoing research, including publications from Cadet-Taïrou et al. (2018), 
Jauffret-Roustide and Cailbault (2018) and Jangal et al. (2021). These references are available in the reference list.  
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Country profiles’ for Austria, Denmark and Latvia. The experts from Denmark and Latvia shared 
their views on the profiles and discussed the identified priorities for action.  
Preliminary analysis showed an increased risk of death for people who use drugs compared with the 
general population. This was verified in the overall literature review and questionnaires returned by all 
participating countries. This was illustrated in the selected countries. The scale of the excess risk and 
the cause-specific mortality rates varied. Highlighting these differences and the specific risk (for 
example related to HIV death in Latvia) should inform policy-making. ACTION: interested countries to 
ask for support from the EMCDDA to prepare their ‘country drug mortality profiles’; 
EMCDDA/contractors to take comments into account and revise the European overview and the 
profiles.  
Mortality cohort study in Lithuania 
Presentation by Aušra Želvienė, Lithuania 
A comprehensive cohort study is being conducted for the first time in Lithuania, in accordance with 
the EMCDDA recommendations. The study aims to collect data of deaths of persons who used drugs 
and psychotropic substances; to obtain comparable data using a standardised data collection 
methodology adapted to Lithuania; to report standard data to the EMCDDA. The study compared 
mortality, life expectancy and other indicators of drug and psychotropic substance users (study group) 
with those of the general European population. The study population includes national citizens who in 
2017 accessed Lithuanian health care institutions for mental and behavioural disorders when using 
narcotic and psychotropic substances. The enrolment (n = 263 patients) started in January 2017 and 
the follow-up ended in December 2020. Fourteen deaths were recorded (9 males and 5 females). 
Eight deaths occurred during the first year of follow-up. The main causes of death were opioid use (9 
cases) and HIV (3 cases). HCV was mentioned in four death certificates. The standardised mortality 
ratio (SMR) was 12.7/1 000 person-years (PY) (43.2/1 000 PY among females compared with 
9.1/1 000 PY among males). Study participants had a 21.9 times higher risk of death compared with 
the general European population. The excess risk was higher among females (SMR 30.5) compared 
with males (13.3). 
OAT in Czechia, Denmark and Norway: adherence, trajectories and outcomes 
Presentation by Viktor Mravcik, Czechia  
An update was provided on the project initiated last year (Gabrhelik et al., 2021a). The project aims to 
study OAT adherence trajectories and to identify factors associated with improved outcomes for OAT 
patients across Czechia, Denmark and Norway. It aims to further improve OAT and the 
understanding of the key elements of treatment process and outcome. The data were collected from 
several nationwide health and population registers. A total of approximately 20 000 OAT patients over 
the last two decades in all three countries are included in the study. The full paper describes the 
sources, settings and expected outcomes on the study. Besides overall mortality and overdose-
specific mortality, somatic and psychiatric morbidity will be explored. Country-based analysis will be 
followed by combined analysis. First analysis is focused on the comparison of mortality of OAT 
patients in Czechia and Denmark. Preliminary analysis shows differences between crude mortality 
(higher in Denmark) as well as a different effect of OAT. Adjusted/stratified analysis is planned to 
control for possible confounders. The differences in the treatment systems and settings will be 
discussed.  
Prenatal illicit drugs and OAT exposure and adverse neonatal outcomes 
This international Czech-Scandinavian study builds on a previous joint research project based on 
Czech and Norwegian registers. It aimed to explore the consequences in children prenatally exposed 
Updates from the annual meeting of the EMCDDA DRD expert network: 30/09 – 1/10 2021 
8 
 
to illicit drugs and opioid agonist treatment (Gabrhelik et al., 2016). Analysis showed a substantial 
impact of socioeconomic characteristics and prenatal care on pregnancy and neonatal outcomes 
(Mravcik et al., 2020). A series of analyses focusing on prenatal exposure to OAT showed negative 
outcomes comparable to a control group of pregnant women with substance use disorders not being 
in OAT, higher as compared to general population of pregnant women (Handal et al., 2019; 
Nechanska et al., 2018; Skurtveit et al., 2019). 
The most recent published paper from the collaboration explored prenatal methamphetamine 
exposure and adverse neonatal outcomes in Czechia (Gabrhelik et al., 2021b). The study explored 
the predictors for deliveries and the morbidity of children up to 3 years of age. The study again 
showed that although the observed negative outcomes were large in the maternal methamphetamine-
exposed new-borns, the adjustment had a profound effect on the comparison with the general 
population, indicating the large influence of lifestyle and socio-economic factors in these high-risk 
pregnancies. Maternal methamphetamine-exposed new-borns had better neonatal outcomes 
compared with new-borns exposed to opioids.  
Drug-related deaths data to inform policy-making  
A new selection of cases for drug-related deaths reporting from Belgium 
Presentation by Jérôme Antoine, Belgium 
Over the last years, the Belgian drug-related deaths data have experienced delays and probable 
underestimation, in part due to the specific administrative organisation of the country, and also to the 
national ICD-coding practices. A new set of ICD-10 codes extracted from the general mortality 
register (GMR) is now explored by the national experts, to better capture the true scale of drug-related 
deaths in the country and to facilitate comparisons with the other countries. The set of codes is 
completed by the codes T43.8 and T43.9 codes, i.e. ‘other psychotropic drugs, not elsewhere 
classified/psychotropic drug, unspecified’. The use of the new selection results in an increase of 48 % 
in the number of drug-induced deaths reported over the period 2000-2017 (and a 114 % increase in 
Wallonia in particular) compared with the definition previously used. The mortality rates among adults 
aged 15-64 increases from 14 to 19 deaths per million population in 2017 (latest year with available 
data). This new selection is thought to be more sensitive, not at the cost of less specificity. However, it 
is noted that more than 6 in 10 cases are coded as unspecified drugs, versus less than 5 in 10 with 
the previous selection. Discussion followed on the best way to report and to communicate these 
revised numbers.  
So-Prep project: preparedness for a rise in synthetic opioids use  
Presentation by Katri Abel-Ollo, Estonia 
The project aims to explore and define how the EU countries can be prepared and equipped facing a 
continued rise in synthetic opioids prevalence, use and incidents. So-Prep aims to produce evidence-
based recommendations for Europe on how to prepare for a potential SO (synthetic opioids) crisis. 
The partners of the project include Ghent University (Belgium), THL (Finland), TAI (Estonia), 
Correlation – European Harm Reduction Network, Frankfurt University (Germany) and the Trimbos 
Institute (The Netherlands). The specific objectives of the projects are:  
• gaining a better insight and understanding of the current use and trends of SO and related 
health needs in Europe; 
• strengthening the national health system SO preparedness; 
• developing an evidence-based toolkit with implementation guides describing good practice 
monitoring and responses to SO in Europe.  




GMR data and comparability of the DRD data 
In some countries, T-codes are not or little used in the coding of the cause of deaths in the general 
mortality register (GMR). This limits the possibility to fully apply the European DRD protocol (i.e. 
associating a range of poisoning codes – X41, 61, 42, 62, 44, 64, Y11, 12, 14; with T-codes for 
external causes, namely selected drugs). The unsystematic use of T-codes is a limitation, for example 
in Belgium, France, Spain and Poland, where ‘proxies’ of the European definition are used, which 
include the broader X44 definition, despite the absence of T-codes that are required for compatibility 
with the European definition. 
Furthermore, there are other differences across countries that limit the comparability of the overdose 
data. The other differences include, but are not limited to, the autopsy rates for suspected drug-
induced deaths cases, the extent of the toxicological investigations, and how their results are reported 
and used for the certification of the cause of death. This information should be reflected as much as 
possible in the presentation of the national data.  
Suggestions in the light of this discussion. 
• Alongside the usual European comparisons across countries, more emphasis could be placed 
in describing trends over time within countries; and also, the limitations or specificities of the 
available data.  
• Some groups of countries could be shown together, based on the ‘quality’ or completeness of 
the data; groups could also be formed based on the general characteristics of the high-risk drug 
use problem in the country.  
• Trends in the number of young drug-induced deaths cases (e.g. those younger than 30 years) 
should be highlighted.  
• Overall, discussion should continue with the EMCDDA and the interested focal points and 
experts on the best ways to present the European situation, alongside the national specificities.  
• GMR data should be reported by all countries, independent of the quality issues identified so 
far. This will help to understand their possible limitations and to improve this data resource. 
• Many drug-induced deaths are coded with unspecified or ‘unknown’ substances in some 
countries. That relates in part to the limitation of the current ICD-coding. The focal points should 
complement as much as possible their GMR data with data from the special mortality registers, 
in order to provide information of the substances identified in post-mortem toxicology.  
• Alternatively, when no data are available directly from a forensic source, the focal points are 
encouraged to report the number of cases found with heroin, methadone or cocaine, based on 
the respective ICD codes of the cases extracted from the GMR. 
Complexity and diversification of the opioids landscape 
Discussion followed on the different opioids identified as sources of concern across the countries. In 
Estonia, fentanyl-related deaths have decreased from a record of 114 deaths in 2016 to fewer than 
30 deaths in 2019 (most recent data available) – still under validation. In this context, high-risk drug 
use now involves more alpha-PVP and amphetamines. In Czechia, the opioid problem is now 
characterised by a combination of fentanyl, morphine, hydromorphone and tramadol, in a context of 
rather low coverage of OAT.  
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Suggestions: It was noted that the new template ST6 allows specific reporting for more drugs 
mentioned in the post-mortem findings, compared with the previous template. The drugs newly 
added include opioids (fentanyl and tramadol), pregabalin and benzodiazepines. The EMCDDA 
encourages the focal points to report drug-specific data as much as possible, in order to describe 
trends and inform policy-making. 
Finally, the question was raised on how the national estimated populations of opioid users capture the 
different possible ‘sub groups’ of opioid users, or patterns of opioid use, and how these estimates can 
help understand the needs for interventions.  
Conclusions and next steps 
Most recent developments and concerns 
• In the context of the continuing COVID-19 pandemic, the DRD expert network is sharing up to 
date information on drug-related deaths. While there is uncertainty about the impact of the 
pandemic on the multifaceted problem of drug-related harms and deaths, continuous robust 
action-oriented monitoring is needed.  
• Preliminary data for 2020 do not suggest that the European Union has experienced a crisis of 
drug-related deaths, in contrast to the crisis observed in North America. However, a few 
countries – including some of the largest countries – do not have 2020 data yet (e.g. France, 
Germany, Spain) and caution is required in interpreting the European-level data currently 
available.  
• The opioids landscape (prevalence, use and harm) is complex and rapidly evolving across 
Europe. There are some differences between countries in the populations using opioids, and in 
the market for and use of opioids including heroin, methadone, buprenorphine, fentanyl, 
tramadol, new opioids and a range of prescription opioids. Preparedness needs to be based on 
sound data analysis. Signals of increases in the number of deaths related to opioids are 
confirmed in some countries.  
Progress with the quality and utility of the data to inform policy-making 
• All countries – with one or two exceptions in 2021 – report annual data from one, and often two, 
complementary sources as recommended.  
• New special registers – typically based on forensic laboratories – are developing in 2020-21 
and will provide more timely and complete information on the drugs implicated in the deaths, 
e.g. in the Netherlands.  
• Several countries have refined their extraction of data from their general mortality registers in 
2020-21, e.g. Belgium and Greece.  
• Several countries have recently initiated new studies on the overall mortality of drug users (e.g. 
Croatia) and some European joint analyses are conducted (e.g. in Czechia, Denmark and 
Norway).  
• The cross-validation of all these will provide more robust and useful data to inform policy-
making. 
Rolling out of responses across Europe; Canadian overdose crisis; crack in France 
• The rolling out of evidence-based responses, including take-home naloxone programmes, is 
progressing in many countries. However, although OAT is a cornerstone of the evidence-based 
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prevention of deaths among people who use opioids, there is a gap in estimating the coverage 
of OAT among eligible opioid users in Europe.  
• The overdose crisis in Canada since the beginning of the pandemic is developing – overdose 
mortality rates are 15 times higher in British Columbia compared with the average in Europe. 
The crisis is mainly driven by fentanyl, in a context of a suboptimal access to care and 
treatment.  
• Crack cocaine use has been increasing in Paris region since the 2000s and it is estimated that 
13 000 users have complex unmet health and social needs. Despite stigma and opposition, 
additional health services with safe consumption facilities have been suggested to support and 
complement the currently insufficient healthcare provision. 
Mortality studies: beyond overdose, excess risk of deaths from all causes 
• Most countries have conducted studies to measure the overall mortality among people who are 
using drugs in Europe. All studies point to an excess mortality risk among those using drugs 
compared with the risk observed in the general population of people of the same sex and age.  
• Beyond overdose deaths, the risk of death increases for deaths due to HIV/AIDS, other 
infections, liver disease including viral hepatitis, suicide, cancer and violence. Users in some 
countries or some settings or circumstances are at particularly high risk of death. A ‘European 
overview’ and several ‘Mortality country profiles’ are in preparation.  
Next steps 
• An ad hoc online DRD meeting can be organised over the next few weeks, in particular for 
some DRD experts to present their new data or specific research.  
• As was done for the trendspotter report published in May 2021, some countries volunteered to 
report monthly data for the year 2020 if the exercise is carried out again. This will be followed 
up with the interested countries as necessary. 
• The date of the next DRD expert meeting will be confirmed in due course. An option would be 
back to back with the Addictions conference, to be held in Lisbon, Portugal in November 2022.  
Resources 
• The most recently published DRD data are available in the Statistical Bulletin Also available 
online is a ‘questions and answers’ page on drug-related deaths, updated in August 2021. 
Experts from the DRD network can access the restricted DRD area, where additional material 
can be available.  
The DRD meeting web page is continuously updated. Participating experts and speakers are invited 
to suggest papers/resources for upload where possible, or links to be added on the meeting page. 
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